Neutral
Calamos Advisors LLC increased its holdings in Pfizer Inc. by 3.2% in the fourth quarter, bringing its total stake to 1,919,276 shares valued at $47.7...
Neutral
Pfizer is set to unveil significant oncology pipeline updates at the ASCO 2026 Annual Meeting, showcasing new clinical data for several marketed and p...
Egypt's Ministry of Health held talks with Pfizer representatives to bolster pharmaceutical manufacturing, vaccine production, and medical innovation ...
Bullish
Pfizer and Astellas have received FDA Priority Review for PADCEV plus Keytruda as a perioperative treatment for muscle-invasive bladder cancer, a deve...
Bullish
CICC has initiated coverage of Pfizer Inc. (PFE) with an Outperform rating and a $33 price target. This follows Pfizer's announcement of positive topl...
Neutral
First Horizon Corp trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 20.1% in the fourth quarter, according to its most recent Fo...
Neutral
Pfizer is transitioning its focus from COVID-19 vaccines to oncology, immunology, and rare diseases to drive future growth. The company's strategy inv...
Neutral
UBS Group AG has increased its price target for Pfizer Inc. (PFE) to $27 from $25, while maintaining a Neutral rating. This adjustment follows UBS's Q...
Neutral
BofA has reduced its price target for Pfizer (PFE) from $27 to $26, maintaining a Neutral rating, as part of its Q1 preview across large-cap pharma an...
Bullish
This article compiles various trade ideas for Pfizer Inc. (PFE) from different analysts and traders on TradingView. The ideas range from bullish predi...
Bullish
Artificial intelligence (AI) is already significantly transforming cancer care, particularly in streamlining clinical trial processes and drug discove...